Editorial, Adv Genet Eng Biotechnol Vol: 1 Issue: 1
Omics-Based CHO Cell Engineering – Entrance into Post-Genomic Era
| Yeon-Gu Kim* |
| 1Biotechnology Process Engineering Center, KRIBB, Daejon 305-806, Korea |
| Corresponding author : Dr. Yeon-Gu Kim Biotechnology Process Engineering Center, KRIBB, Daejon 305-806, Korea Tel: 82-42-860-4512; Fax: 82-42-860-4529 E-mail: ygkim@kribb.re.kr |
| Received: July 20, 2012 Accepted: July 23, 2012 Published: July 27, 2012 doi:10.4172/2324-9021.1000e103 |
| Citation: Kim YG (2012) Omics-Based CHO Cell Engineering ��? Entrance into Post-Genomic Era. Adv Genet Eng Biotechnol 1:1. doi:10.4172/2324-9021.1000e103 |
Abstract
Omics-Based CHO Cell Engineering – Entrance into Post-Genomic Era
Chinese hamster ovary cells (CHO) cells have been the most commonly used mammalian host for the production of therapeutic proteins since the first therapeutic protein from recombinant mammalian cells, tissue plasminogen activator (tPA, Genentech, USA) synthesized in CHO cells, was approved for clinical use in 1987. Despite the availability of various mammalian cell lines (such as BHK, HEK-293, HeLa, NS0, and PerC6), nearly 70% of all recombinant protein therapeutics produced today are made in CHO cells.